TRIMTECH Therapeutics
To add a bio or update company history, please click update information.
News from TRIMTECH Therapeutics
TRIMTECH Therapeutics
23 Jun 2026
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
TRIMTECH Therapeutics
5 Mar 2025
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
TRIMTECH Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £35m
- trimtechtherapeutics.com
- Update Information
More venture news
- 2 Sept 2026
PharosynPharosyn secures £2.2m in funding led by Moonfire to improve commercial decision-making inside pharma companies
EquityLife Sciences - 12 Aug 2026
CN BioCN Bio secures a £180k Innovate UK grant to develop organ-on-a-chip system for drug behaviour predictions
GrantLife Sciences - 5 Aug 2026
MironidMironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences
